Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Print publication year: 2012
  • Online publication date: August 2012

8 - Testosterone and bone

Related content

Powered by UNSILO

8.11 References

AminS, ZhangY, FelsonDT, SawinCT, HannanMT, WilsonPW, KielDP (2006) Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 119:426–433
AndersonFH, FrancisRM, PeastonRT, WastellHJ (1997) Androgen supplementation in eugonadal men with osteoporosis: effects of six months’ treatment on markers of bone formation and resorption. J Bone Miner Res 12:472–478
AraujoAB, TravisonTG, LederBZ, MckinlayJB (2008) Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab 93:2135–2141
AuyeungTW, LeeJS, KwokT, LeungJ, OhlssonC, VandenputL, LeungPC, WooJ (2011) Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men. Eur J Endocrinol 164:811–817
BaimS, LeonardMB, BianchiML, HansDB, KalkwarfHJ, LangmanCB, RauchF (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 11:6–21
BaniwalSK, KhalidO, SirD, BuchananG, CoetzeeGA, FrenkelB (2009) Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 23:1203–1214
Barrett-ConnorE, MuellerJE, Von MuhlenDG, LaughlinGA, SchneiderDL, SartorisDJ (2000) Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85:219–223
BasariaS, DobsAS (2001) Hypogonadism and androgen replacement therapy in elderly men. Am J Med 110:563–572
BehreHM, KlieschS, LeifkeE, LinkTM, NieschlagE (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390
BertelloniS, BaroncelliGI, BattiniR, PerriG, SaggeseG (1995) Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty. J Bone Miner Res 10:1488–1495
BertelloniS, BaroncelliGI, FerdeghiniM, PerriG, SaggeseG (1998) Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab 83:4280–4283
BilezikianJP, MorishimaA, BellJ, GrumbachMM (1998) Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599–603
BjorneremA, AhmedLA, JoakimsenRM, BerntsenGK, FonneboV, JorgensenL, OianP, SeemanE, StraumeB (2007) A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromso Study. Eur J Endocrinol 157:119–125
BonewaldLF, JohnsonML (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42:606–615
BoonenS, VanderschuerenD, GeusensP, BouillonR (1997) Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men. Int J Androl 20:134–143
BoonenS, OrwollES, WenderothD, StonerKJ, EusebioR, DelmasPD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719–725
BouillonR, BexM, VanderschuerenD, BoonenS (2004) Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 89:6025–6029
BoyleWJ, SimonetWS, LaceyDL (2003) Osteoclast differentiation and activation. Nature 423:337–342
BrownJE, EllisSP, LesterJE, GutcherS, KhannaT, PurohitOP, MccloskeyE, ColemanRE (2007) Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 13:5406–5410
Burnett-BowieSA, MckayEA, LeeH, LederBZ (2009) Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 94:4785–4792
CallewaertF, VenkenK, OphoffJ, De GendtK, TorcasioA, Van LentheGH, Van OosterwyckH, BoonenS, BouillonR, VerhoevenG, VanderschuerenD (2009) Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J 23:232–240
CallewaertF, BoonenS, VanderschuerenD (2010a) Sex steroids and the male skeleton: a tale of two hormones. Trends Endocrinol Metab 21:89–95
CallewaertF, SinnesaelM, GielenE, BoonenS, VanderschuerenD (2010b) Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J Endocrinol 207:127–134
CaraniC, QinK, SimoniM, Faustini-FustiniM, SerpenteS, BoydJ, KorachKS, SimpsonER (1997) Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337:91–95
CenterJR, NguyenTV, SchneiderD, SambrookPN, EismanJA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882
CrawfordBA, LiuPY, KeanMT, BleaselJF, HandelsmanDJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176
DaniellHW (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439–444
De LaetCE, Van HoutBA, BurgerH, HofmanA, PolsHA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315:221–225
De LaetCE, Van HoutBA, BurgerH, WeelAE, HofmanA, PolsHA (1998) Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 13:1587–1593
DoranPM, RiggsBL, AtkinsonEJ, KhoslaS (2001) Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 16:2118–2125
DucyP (2000) Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 219:461–471
DunkelL, WickmanS (2002) Novel treatment of delayed male puberty with aromatase inhibitors. Horm Res 57 (Suppl 2):44–52
EmpanaJP, Dargent-MolinaP, BreartG (2004) Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 52:685–690
EnsrudKE, ThompsonDE, CauleyJA, NevittMC, KadoDM, HochbergMC, SantoraAC 2nd, BlackDM (2000) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 48:241–249
FabbriA, GiannettaE, LenziA, IsidoriAM (2007) Testosterone treatment to mimic hormone physiology in androgen replacement therapy. A view on testosterone gel and other preparations available. Expert Opin Biol Ther 7:1093–1106
Falahati-NiniA, RiggsBL, AtkinsonEJ, O'fallonWM, EastellR, KhoslaS (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553–1560
FechtenbaumJ, CropetC, KoltaS, HorlaitS, OrcelP, RouxC (2005) The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 16:2175–2179
FerlinA, SchipillitiM, VinanziC, GarollaA, Di MambroA, SeliceR, LenziA, ForestaC (2011) Bone mass in subjects with Klinefelter syndrome: role of testosterone levels and androgen receptor gene CAG polymorphism. J Clin Endocrinol Metab 96:E739–E745
FinkelsteinJS, KlibanskiA, NeerRM, GreenspanSL, RosenthalDI, CrowleyWF Jr (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 106:354–361
FinkelsteinJS, NeerRM, BillerBM, CrawfordJD, KlibanskiA (1992) Osteopenia in men with a history of delayed puberty. N Engl J Med 326:600–604
FinkelsteinJS, KlibanskiA, NeerRM (1999) Evaluation of lumber spine bone mineral density (BMD) using dual energy X-ray absorptiometry (DXA) in 21 young men with histories of constitutionally-delayed puberty. J Clin Endocrinol Metab 84:3400–3401; author reply:3403–3404
FriedLP, TangenCM, WalstonJ, NewmanAB, HirschC, GottdienerJ, SeemanT, TracyR, KopWJ, BurkeG, McburnieMA (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156
GaoW, ReiserPJ, CossCC, PhelpsMA, KearbeyJD, MillerDD, DaltonJT (2005) Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 146:4887–4897
Goderie-PlompHW, Van Der KliftM, De RondeW, HofmanA, De JongFH, PolsHA (2004) Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab 89:3261–3269
HaradaS, RodanGA (2003) Control of osteoblast function and regulation of bone mass. Nature 423:349–355
HoltG, KhawKT, ReidDM, CompstonJE, BhallaA, WoolfAD, CrabtreeNJ, DalzellN, Wardley-SmithB, LuntM, ReeveJ (2002) Prevalence of osteoporotic bone mineral density at the hip in Britain differs substantially from the US over 50 years of age: implications for clinical densitometry. Br J Radiol 75:736–742
HuberDM, BendixenAC, PathroseP, SrivastavaS, DiengerKM, ShevdeNK, PikeJW (2001) Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142:3800–3808
IsidoriAM, GiannettaE, GrecoEA, GianfrilliD, BonifacioV, IsidoriA, LenziA, FabbriA (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63:280–293
JacksonJA, KleerekoperM, ParfittAM, RaoDS, VillanuevaAR, FrameB (1987) Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 65:53–58
JohnellO, KanisJA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733
KamelHK (2005) Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging 22:741–748
KanisJA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936
KanisJA, GluerCC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192–202
KanisJA, JohnellO, OdenA, SemboI, Redlund-JohnellI, DawsonA, De LaetC, JonssonB (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674
KanisJA, JohnellO, OdenA, JohanssonH, MccloskeyE (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397
KatznelsonL, FinkelsteinJS, SchoenfeldDA, RosenthalDI, AndersonEJ, KlibanskiA (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358–4365
KawanoH, SatoT, YamadaT, MatsumotoT, SekineK, WatanabeT, NakamuraT, FukudaT, YoshimuraK, YoshizawaT, AiharaK, YamamotoY, NakamichiY, MetzgerD, ChambonP, NakamuraK, KawaguchiH, KatoS (2003) Suppressive function of androgen receptor in bone resorption. Proceedings of the National Academy of Sciences of the United States of America 100:9416–9421
KearbeyJD, GaoW, FisherSJ, WuD, MillerDD, DaltonJT (2009) Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats. Pharm Res 26:2471–2477
KelepourisN, HarperKD, GannonF, KaplanFS, HaddadJG (1995) Severe osteoporosis in men. Ann Intern Med 123:452–460
KennyM, PrestwoodKM, GrumanCA, MarcelloKM, RaiszLG (2001) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56:M266–M272
KennyM, PrestwoodKM, GrumanCA, FabregasG, BiskupB, MansoorG (2002) Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 57:M460–M465
KhoslaS, LufkinEG, HodgsonSF, FitzpatrickLA, MeltonLJ 3rd (1994) Epidemiology and clinical features of osteoporosis in young individuals. Bone 15:551–555
KhoslaS, MeltonLJ 3rd, AtkinsonEJ, O'fallonWM, KleeGG, RiggsBL (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274
KhoslaS, AminS, OrwollE (2008) Osteoporosis in men. Endocr Rev 29:441–464
KurlandES, RosenCJ, CosmanF, McmahonD, ChanF, ShaneE, LindsayR, DempsterD, BilezikianJP (1997) Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 82:2799–2805
LanfrancoF, ZirilliL, BaldiM, PignattiE, CorneliG, GhigoE, AimarettiG, CaraniC, RochiraV (2008) A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment. Bone 43:628–635
LippunerK, GolderM, GreinerR (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 16 Suppl 2:S8–S17
LyLP, JimenezM, ZhuangTN, CelermajerDS, ConwayJ, HandelsmanDJ (2001) A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86:4078–4088
ManolagasSC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137
ManolagasSC (2010) From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31:266–300
MaravicM, Le BihanC, LandaisP, FardelloneP (2005) Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporos Int 16:1475–1480
MeierC, NguyenTV, HandelsmanDJ, SchindlerC, KushnirMM, RockwoodAL, MeikleW, CenterJR, EismanJA, SeibelMJ (2008) Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 168:47–54
MeierDE, OrwollES, KeenanEJ, FagerstromRM (1987) Marked decline in trabecular bone mineral content in healthy men with age: lack of association with sex steroid levels. J Am Geriatr Soc 35:189–197
MellstromD, VandenputL, MallminH, HolmbergAH, LorentzonM, OdenA, JohanssonH, OrwollES, LabrieF, KarlssonMK, LjunggrenO, OhlssonC (2008) Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23:1552–1560
MeltonLJ 3rd, LieberMM, AtkinsonEJ, AchenbachSJ, ZinckeH, TherneauTM, KhoslaS (2011) Fracture risk in men with prostate cancer: a population-based study. J Bone Miner Res 26:1808–1815
MisiorowskiW (2010) Parathyroid hormone and its analogues – molecular mechanisms of action and efficacy in osteoporosis therapy. Endokrynol Pol 62:73–78
MorishimaA, GrumbachMM, SimpsonER, FisherC, QinK (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689–3698
NakamuraT, ImaiY, MatsumotoT, SatoS, TakeuchiK, IgarashiK, HaradaY, AzumaY, KrustA, YamamotoY, NishinaH, TakedaS, TakayanagiH, MetzgerD, KannoJ, TakaokaK, MartinTJ, ChambonP, KatoS (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130:811–823
O'ConnellM, TajarA, RobertsS, WuF (2011) Do androgens play any role in the physical frailty of ageing men?J Androl 34:17
OrsiniLS, RousculpMD, LongSR, WangS (2005) Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 16:359–371
PageST, AmoryJK, BowmanFD, AnawaltBD, MatsumotoM, BremnerWJ, TenoverJL (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502–1510
PedersonL, KremerM, JuddJ, PascoeD, SpelsbergTC, RiggsBL, OurslerMJ (1999) Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci USA 96:505–510
PelatC, Van PottelberghI, Cohen-SolalM, OstertagA, KaufmanJM, MartinezM, De VernejoulMC (2007) Complex segregation analysis accounting for GxE of bone mineral density in European pedigrees selected through a male proband with low BMD. Ann Hum Genet 71:29–42
PernowY, GranbergB, SaafM, WeidenhielmL (2006) Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int 78:90–97
PernowY, HaugeEM, LinderK, DahlE, SaafM (2009) Bone histomorphometry in male idiopathic osteoporosis. Calcif Tissue Int 84:430–438
RapadoA, HawkinsF, SobrinhoL, Diaz-CurielM, Galvao-TellesA, ArverS, Melo GomesJ, MazerN, GarciaE, CostaJ, HorcajadaC, Lopez-GavilanesE, MascarenhasM, PapapietroK, Lopez AlvarezMB, PereiraMC, MartinezG, ValverdeI, GarciaJJ, CarballalJJ, GarciaI (1999) Bone mineral density and androgen levels in elderly males. Calcif Tissue Int 65:417–421
RariyCM, RatcliffeSJ, WeinsteinR, BhasinS, BlackmanMR, CauleyJA, RobbinsJ, ZmudaJM, HarrisTB, CappolaR (2011) Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass: the cardiovascular health study. J Clin Endocrinol Metab 96:989–996
ReidIR (1998) Glucocorticoid-induced osteoporosis: assessment and treatment. J Clin Densitom 1:65–73
ReifensteinEC Jr, AlbrightF (1947) The metabolic effects of steroid hormones in osteoporosis. J Clin Invest 26:24–56
ReimNS, BreigB, StahrK, EberleJ, HoeflichA, WolfE, ErbenRG (2008) Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J Bone Miner Res 23:694–704
RingeJD, OrwollE, DaifotisA, LombardiA (2002) Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13:195–199
RockwoodK, MitnitskiA (2007) Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 62:722–727
SchatzlG, MadersbacherS, TemmlC, Krenn-SchinkelK, NaderA, SregiG, LapinA, HermannM, BergerP, MarbergerM (2003) Serum androgen levels in men: impact of health status and age. Urology 61:629–633
SeemanE (2001) Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 86:4576–4584
SeemanE (2003) Periosteal bone formation – a neglected determinant of bone strength. N Engl J Med 349:320–323
SmithEP, BoydJ, FrankGR, TakahashiH, CohenRM, SpeckerB, WilliamsTC, LubahnDB, KorachKS (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056–1061
SmithEP, SpeckerB, BachrachBE, KimbroKS, LiXJ, YoungMF, FedarkoNS, AbuzzahabMJ, FrankGR, CohenRM, LubahnDB, KorachKS (2008) Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab 93:3088–3096
SmithMR, EasthamJ, GleasonDM, ShashaD, TchekmedyianS, ZinnerN (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008–2012
SmithMR, FallonMA, LeeH, FinkelsteinJS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841–3846
SmithMR, EgerdieB, Hernandez TorizN, FeldmanR, TammelaTL, SaadF, HeracekJ, SzwedowskiM, KeC, KupicA, LederBZ, GoesslC (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755
SnyderPJ, PeacheyH, HannoushP, BerlinJA, LohL, HolmesJH, DlewatiA, StaleyJ, SantannaJ, KapoorSC, AttieMF, HaddadJG Jr, StromBL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972
StepanJJ, LachmanM, ZverinaJ, PacovskyV, BaylinkDJ (1989) Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69:523–527
TaesY, LapauwB, VandewalleS, ZmierczakH, GoemaereS, VanderschuerenD, KaufmanJM, T'sjoenG (2009) Estrogen-specific action on bone geometry and volumetric bone density: longitudinal observations in an adult with complete androgen insensitivity. Bone 45:392–397
VandenputL, BoonenS, Van HerckE, SwinnenJV, BouillonR, VanderschuerenD (2002) Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 17:2080–2086
VanderschuerenD, VandenputL, BoonenS, Van HerckE, SwinnenJV, BouillonR (2000) An aged rat model of partial androgen deficiency: prevention of both loss of bone and lean body mass by low-dose androgen replacement. Endocrinology 141:1642–1647
VanderschuerenD, VandenputL, BoonenS, LindbergMK, BouillonR, OhlssonC (2004) Androgens and bone. Endocr Rev 25:389–425
VanderschuerenD, VandenputL, BoonenS (2005) Reversing sex steroid deficiency and optimizing skeletal development in the adolescent with gonadal failure. Endocr Dev 8:150–165
VenkenK, BoonenS, Van HerckE, VandenputL, KumarN, Sitruk-WareR, SundaramK, BouillonR, VanderschuerenD (2005) Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone 36:663–670
VenkenK, De GendtK, BoonenS, OphoffJ, BouillonR, SwinnenJV, VerhoevenG, VanderschuerenD (2006) Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res 21:576–585
VermeulenA, KaufmanJM, GoemaereS, Van PottelbergI (2002) Estradiol in elderly men. Aging Male 5:98–102
WeiJT, GrossM, JaffeCA, GravlinK, LahaieM, FaerberGJ, CooneyKA (1999) Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54:607–611
ZirilliL, RochiraV, DiazziC, CaffagniG, CaraniC (2008) Human models of aromatase deficiency. J Steroid Biochem Mol Biol 109:212–218